- Rapid communication
- Open Access
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
Experimental Hematology & Oncology volume 8, Article number: 24 (2019)
Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L792 mutations, a non-covalent mechanism of osimertinib resistance, using Guardant360 cfDNA testing in a patient with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) whose disease progressed on osimertinib. We subsequently analyzed a large cohort of over 1800 additional patient samples harboring an EGFR T790M mutation and identified a concomitant L792 mutation in a total of 22 (1.2%) cases. In vitro functional assays demonstrated that the EGFR L858R/T790M/L792F/H mutations conferred intermediate-level resistance to osimertinib. Further understanding of potential acquired resistance mechanisms to targeted therapy may help inform treatment strategy in EGFR-mutant NSCLC.
Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a distinct molecular subtype with sensitivity to EGFR-selective tyrosine kinase inhibitors (TKIs) [1,2,3,4]. However, tumors invariably develop resistance to these EGFR TKIs, mediated by on-target genetic alterations within the EGFR tyrosine kinase domain, EGFR-independent mechanisms, or small cell transformation [5, 6]. In initial reports of acquired resistance to first-generation EGFR TKIs erlotinib and gefitinib, 50–60% of cases harbored an EGFR T790M gatekeeper mutation [5, 6]. Osimertinib, an irreversible, third-generation EGFR inhibitor, was developed to target T790M mutation-positive, first-generation TKI-refractory tumors and demonstrated robust efficacy with objective response rates of 61–71% among T790M-positive NSCLC patients [7,8,9]. More recently, osimertinib became the new standard initial therapy in advanced EGFR-mutant NSCLC . Despite its efficacy, patients acquire resistance to osimertinib through various mechanisms including EGFR C797S mutations which eliminate the covalent bonding site for osimertinib, and amplification of MET or ERBB2 (HER2), among others [11,12,13]. The prevalence of C797S mutations may differ depending on the clinical setting and is more common in patients with a pre-existing T790M mutation [14, 15]. Serial assessment of the molecular characteristics of EGFR-mutant NSCLC with each line of therapy will assist in understanding the evolution of on- and off-target mechanisms of resistance and can help guide the development of new therapeutic strategies for patients with resistant disease.
Historically, tumor tissue biopsies have been standard for detection of resistance mechanisms. However, tissue biopsies are inevitably limited by their invasive procedural risk, high cost, treatment delays related to procedure and processing, and inability to capture spatial tumor heterogeneity. In contrast, plasma cell-free DNA (cfDNA) next-generation sequencing (NGS) from peripheral blood allows for safe, global, and repeated longitudinal assessment of mutation dynamics throughout the course of disease and treatment. Therefore, this approach has the potential to accelerate our understanding of TKI resistance.
Here, we report the detection of EGFR L792 resistance mutations via cfDNA sequencing in a patient progressing on osimertinib, their prevalence in a large clinically tested NSCLC cfDNA cohort, and in vitro functional characterization.
A 68-year-old male former smoker with EGFR L858R-mutant metastatic NSCLC presented after progression on multiple lines of therapy, including first-line erlotinib, carboplatin/pemetrexed, docetaxel, followed by afatinib. cfDNA droplet digital PCR identified the EGFR T790M resistance mutation (Fig. 1a). After a short course of cetuximab + afatinib, the patient began osimertinib with disease control; 7 months later, imaging demonstrated progressive disease (Fig. 1b, c). At this time, cfDNA profiling was performed using Guardant360, a highly sensitive and ultra-specific 70-gene NGS panel, which interrogated the entire EGFR coding sequence for SNVs, indels, and gene amplification (Additional file 1: Figure S1) . Twelve somatic alterations were identified, including seven alterations in EGFR (Additional file 1: Table S1). The original L858R activating EGFR mutation was present at a variant allele fraction (VAF) of 16.9%, and the T790M mutation was present at a VAF of 8.4%. In addition, this analysis revealed EGFR C797S (4.6%) and L718Q (0.7%) mutations, both of which have been previously reported as osimertinib resistance mechanisms [11, 12, 17, 18]. Interestingly, three additional tyrosine kinase domain mutations were identified: L792H (1.4%), F795C (0.4%), and L792F (0.1%) (Fig. 1d). While EGFR L792 mutations have recently been reported as resistance mechanisms to osimertinib [19, 20], at the time of this patient’s clinical presentation these were novel findings which spurred further investigation.
Given their genomic proximity, the T790M and C797S mutations were phased to determine allelic origin and found to be in cis, and the F795C mutation appeared on that allele. In contrast, the L792H and L792F variants were in cis to T790M but arose in trans to C797S and to each other. While multiple tissue biopsies over time were not available to determine the temporal sequence of mutational emergence, when mapped against the patient’s treatment history the clonal phylogeny of these EGFR alleles suggested that at least the L792H and L792F mutations arose during osimertinib treatment at the same branch point as the known osimertinib resistance mutation C797S (Fig. 1e). Moreover, structural modeling indicated that each mutation affects a residue that impinges on the ATP-binding pocket (Fig. 1f, g).
Prevalence in a large cfDNA cohort
Given the evidence linking L792H and L792F mutations to osimertinib resistance, the Guardant360 clinical genomic cfDNA database of EGFR-mutant lung cancer samples from 10/14/2015 through 2/4/2019 was retrospectively analyzed to investigate the prevalence of these alterations. 1851 patients were identified whose samples contained EGFR T790M mutations. While detailed clinical information including treatment history is unavailable for this cohort, somatic EGFR T790M mutations are rare outside of the setting of resistance to early-generation TKIs . Of these patients, 22 (1.2%) also had at least one nonsynonymous EGFR L792 alteration identified (Table 1, Additional file 1: Table S2). Of these L792-positive patients, 11 (50%) also had at least one EGFR C797S clone identified. Notably, of the overall cohort of EGFR T790M-positive lung cancer patients, 151 (8.2%) had EGFR C797S identified in their clinical cfDNA testing, considerably more frequent versus the 1.2% prevalence of L792 variants.
Besides the initial case described above, only one other patient was found to have a nonsynonymous EGFR F795 alteration in conjunction with an L792 mutation; this patient’s sample had 14 nonsynonymous EGFR alterations (Additional file 1: Table S2). One additional patient’s sample harbored an EGFR L792R alteration in the absence of a co-occurring EGFR T790M mutation; six other nonsynonymous EGFR alterations were detected in this sample (L717V, L718Q, G796S, C797S, G796R, and S1036R).
Phasing analysis was performed on 27 samples from the 22 unique patients containing an L792F/H/V/P/R or F795C/L mutation. As in the initial case described above, the L792 F/H/V/P/R and F795C/L alterations were invariably present subclonal to and frequently in cis with EGFR T790M, but independent of one another, C797S, and other osimertinib resistance alterations (Additional file 1: Table S3). The recurrence of these mutations across multiple patients supports the hypothesis that these variants confer a selective advantage compatible with osimertinib resistance. However, the relatively low frequency with which these variants are observed and lower VAFs at which they occur suggest that this advantage may be less potent than that conferred by C797S.
To test the hypothesis that the L792F/H mutations confer resistance to osimertinib, we characterized the oncogenic activity of the mutants using a high-throughput functional in vitro assay . Cells were transfected with EGFR expression constructs encoding an L858R sensitizing mutation, T790M resistance mutation, and one additional putative resistance mutation. Downstream signaling pathway activation—namely, MAPK/ERK and JAK-STAT—was assessed by measuring nuclear translocation of two reporters (ERK2 and STAT3) which shuttle from the cytoplasm to the nucleus upon pathway activation . As expected, L858R/T790M induced activation of both MAPK/ERK and JAK-STAT pathways, which was inhibited by osimertinib in a dose-dependent manner (Fig. 2b, c). In contrast, L858R/T790M/C797S demonstrated resistance to osimertinib at all doses (p = 0.004 for the MAPK pathway and p = 0.004 for the JAK\STAT pathway, students t = test), compatible with irreversible loss of the osimertinib binding site. Importantly, the addition of L792H (p = 0.086 for the MAPK pathway, students t = test) and, to a lesser degree, L792F (p = 0.085 for the MAPK pathway, students t = test) to L858R/T790M induced intermediate levels of resistance that were overcome by increasing levels of osimertinib. This can be also seen in a 2-times higher AUC value as compared to L858R alone (Fig. 2d).
In this report, through clinical cfDNA NGS we identify EGFR L792 mutations in 22 of 1851 (1.2%) NSCLC patient cases with an EGFR T790M mutation. These L792 mutations appear to be a non-covalent mechanism of osimertinib resistance in which alterations in the EGFR ATP binding pocket diminish, but do not entirely prevent, osimertinib binding. In vitro assays suggest that increasing doses of osimertinib may overcome this resistance and inhibit EGFR activity, compatible with steric hindrance of drug binding or altered affinity to the drug or ATP rather than elimination of the binding site.
These results are consistent with recent reports of EGFR L792 mutations. Chen et al.  reported L792 mutations identified through cfDNA testing of plasma or pleural effusion in three patients with NSCLC progressing on osimertinib, with a follow-up study from the same group  identifying mutations at this residue in 11/93 (12%) of Chinese patients with osimertinib-resistant lung cancer.
There are inherent limitations to examining the prevalence of EGFR L792 mutations in the context of co-occurring T790M mutations. This approach was used due to the unavailability of treatment history details for genomic data from a commercial laboratory. With the recent approval of osimertinib for first-line use, this genomic context may not apply moving forward. Nishino et al.  found that EGFR L792 mutations in combination with L858R but in the absence of T790M conferred moderate resistance to osimertinib in vitro. Future studies examining the prevalence and functional effect of EGFR L792 mutations in the absence of T790M may clarify how broadly this data may be extrapolated in the dynamic landscape of drug approvals and treatment sequences.
Notably, the case described in detail above was found to have multiple EGFR mutations on cfDNA NGS, as did many other cases subsequently identified in the cohort prevalence analysis (Additional file 1: Table S2). The emergence of multiple alterations across the course of disease and treatment makes it increasingly difficult to delineate the isolated impact of any individual mutation in the acquired resistance process; this limitation of traditional analysis heightens the need for repeated comprehensive genomic profiling in the setting of clinical progression to capture the full context of changes under treatment pressure. The evolution of multiple on-target alterations underscores the complexity of the genomic landscape that can emerge in the setting of TKI resistance and highlights the importance of repeat genomic analysis, and in particular cfDNA NGS to non-invasively capture heterogeneous resistance, in detecting potentially targetable genomic alterations over the disease course.
Availability of data and materials
The datasets generated and analyzed during the current study are not publicly available due to constraints given the origin of the genomic data from a clinical testing laboratory.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.
Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–42.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8.
Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.
Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–7.
Jänne PA, Yang JCH, Kim D-W, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689–99.
Yang JCH, Ahn M-J, Kim D-W, Ramalingam SS, Sequist LV, Su W-C, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35:1288–96.
Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–40.
Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25.
Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol. 2015;1:982–4.
Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560–2.
Ramalingam SS, Yang JCH, Lee CK, Kurata T, Kim D-W, John T, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:841–9.
Ramalingam SS, Cheng Y, Zhou C, Ohe Y, Imamura F, Cho BC, et al. LBA50 Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29. https://academic.oup.com/annonc/article/doi/10.1093/annonc/mdy424.063/5142018. Accessed 18 Nov 2018.
Papadimitrakopoulou VA, Wu Y-L, Han J-Y, Ahn M-J, Ramalingam SS, John T, et al. LBA51 analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol. 2018;29. https://academic.oup.com/annonc/article/doi/10.1093/annonc/mdy424.064/5142034. Accessed 18 Nov 2018.
Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS ONE. 2015;10:e0140712.
Ercan D, Choi HG, Yun C-H, Capelletti M, Xie T, Eck MJ, et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res. 2015;21:3913–23.
Bersanelli M, Minari R, Bordi P, Gnetti L, Bozzetti C, Squadrilli A, et al. L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC. J Thorac Oncol. 2016;11:e121–3.
Chen K, Zhou F, Shen W, Jiang T, Wu X, Tong X, et al. Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC. J Thorac Oncol. 2017;12:e65–8.
Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018;24:3097–107.
Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol. 2014;25:423–8.
Golbstein J, Tocker Y, Sharivkin R, Tarcic G, Vidne M. A novel high-throughput multispectral cell segmentation algorithm. In: Valdés Hernández M, González-Castro V, editors. Medical image understanding and analysis. Cham: Springer International Publishing; 2017. p. 754–66.
Nishino M, Suda K, Kobayashi Y, Ohara S, Fujino T, Koga T, et al. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. Lung Cancer. 2018;126:149–55.
The authors have no funding sources to disclose.
Ethics approval and consent to participate
This study has obtained appropriate institutional review board approval for analysis of deidentified and limited data sets which waived the need for individual patient informed consent.
Consent for publication
SRF, AK, RBL, and RJN are employees and shareholders of Guardant Health, Inc. OZ and GT are employees of NovellusDx. JJL received honoraria from or served as a consultant for Chugai and Boehringer-Ingelheim and received institutional research funding from Loxo Oncology. ATS has served as a compensated consultant or received honoraria from Pfizer, Novartis, Genentech/Roche, Ariad/Takeda, Ignyta, LOXO, Bayer, Chugai, Blueprint Medicines, KSQ Therapeutics, Daiichi Sankyo, EMD Serono, Taiho Pharmaceutical, TP Therapeutics, Foundation Medicine, Guardant, Natera, Servier, and Syros; has received institutional research funding from Pfizer, Novartis, Roche/Genentech, Ariad, Ignyta, and TP Therapeutics; and has received travel support from Pfizer and Roche/Genentech. The remaining authors do not report relevant competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Fairclough, S.R., Kiedrowski, L.A., Lin, J.J. et al. Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort. Exp Hematol Oncol 8, 24 (2019) doi:10.1186/s40164-019-0148-7
- Cell-free DNA
- Genomic evolution
- Acquired resistance
- Functional studies